The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Cathy Eng, MD, FACP, professor, director, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Network Clinical Research, associate medical director, Colorectal Center, University of Texas MD Anderson Cancer Center, discusses emerging agents for the treatment of patients with anal cancer.

Contemporary efforts toward defining molecular subsets of colorectal cancer can potentially aid our ability to refine therapy and improve outcomes for patients with colorectal cancer.

James Allison, chair of Immunology at the University of Texas MD Anderson Cancer Center, discusses promising data regarding the use of immunotherapies in melanoma. Allison is particularly excited about a trial, presented at the Society of Melanoma Research Congress, which looked at the combination of PD-L1 inhibitors with a BRAF-targeted agent.

James Allison, PhD, discusses the rapidly expanding field of immunotherapy in melanoma.

William G. Wierda, MD, PhD, gives a better understanding of the changing landscape of chronic lymphocytic leukemia and how treatment options vary among different patient subtypes.

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Alessandra Ferrajoli, MD, discusses the impact of the CLL11 and COMPLEMENT 1 trials, as well as other treatments that may be beneficial to the elderly chronic lymphocytic leukemia population.

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia.

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Lack of improvement in failure-free survival for patients with follicular lymphoma has fueled interest in new treatment strategies that might offer promise of better outcomes.

Immunotherapy pioneer James P. Allison, PhD, has been named the 2015 recipient of the Lasker-DeBakey Clinical Medical Research Award by the Albert and Mary Lasker Foundation.

Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses minimal residual disease in chronic lymphocytic leukemia (CLL). 

Robert L. Coleman, MD, The University of Texas MD Anderson Cancer Center, discusses the next steps following results of the ARIEL2 trial, which aimed to identify patients with ovarian cancer most likely to respond to rucaparib using tumor genetic analysis.

The experiment with bundled care in oncology is moving forward despite mixed results and lingering concerns about the administrative difficulty of implementation, potential care compromises, and whether innovation can thrive under fixed payments.

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

James P. Allison, PhD, was honored in the Scientific Advances category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

The identification of a deletion 20q in a patient with chronic lymphocytic leukemia may not indicate they have developed a myelodysplastic syndrome as was previously assumed.

William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses how bevacizumab could be effective in tumor types beyond ovarian cancer.

James P. Allison, PhD, was recently honored with two prestigious awards: the Science of Oncology Award from ASCO and the Pezcoller Foundation–AACR International Award for Cancer Research.

In an interview with OncLive, Robert C. Bast, Jr, MD, discussed his research using CA-125 levels and p53-autoantibodies as biomarkers for early detection of ovarian cancer.

OncLive spoke with Elizabeth A. Mittendorf, MD, PhD, to learn more about the PRESENT trial and the potential impact of nelipepimut-S in breast cancer.

In an interview with OncLive, William G. Wierda, MD, PhD, discusses the changing role of chemotherapy in the management of CLL and the integration of novel agents into clinical practice.

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.

James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.